Myocardial Infarction
📧 Sign up to get email alerts when something new happens for Myocardial Infarction.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-09-26FDA Approved: LISINOPRIL — Supplemental Application (Solco healthcare U.S., LLC)
The FDA approved a supplemental application for lisinopril filed by Solco Healthcare U.S., LLC under an ANDA. The action authorizes changes …
-
FDA approval · 2019-09-23FDA Approved: BIVALIRUDIN — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for Bivalirudin submitted by Mylan Institutional LLC.
-
FDA approval · 2019-09-23FDA Approved: BIVALIRUDIN — Supplemental Application (Meitheal Pharmaceuticals Inc.)
FDA approved a supplemental application for bivalirudin by Meitheal Pharmaceuticals, marking regulatory approval of a modification to the dr…
-
FDA approval · 2019-09-20FDA Approved: CLOPIDOGREL — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for clopidogrel bisulfate manufactured by Aurobindo Pharma Limited, enabling continued marketing…
-
FDA approval · 2019-09-20FDA Approved: VALSARTAN — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approves a supplemental application for VALSARTAN by Amneal Pharmaceuticals LLC (ANDA 204011) to support the generic product.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-09-18Clinical Trial Update: P3AMI Antiplatelet Trial [Phase 4]
Phase 4 clinical trial update for the P3AMI Antiplatelet trial completed with results posted in 2019.
-
FDA approval · 2019-09-13FDA Approved: VALSARTAN — Supplemental Application (Alembic Pharmaceuticals Limited)
The FDA approved a supplemental application for valsartan from Alembic Pharmaceuticals Limited (ANDA 091367).
-
FDA approval · 2019-09-12FDA Approved: CLOPIDOGREL — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for clopidogrel from Amneal Pharmaceuticals LLC under ANDA 203751, confirming changes to the approve…
-
CLINICAL_TRIALS trial_result · 2019-09-06Clinical Trial Update: Alirocumab in Patients With Acute Myocardial Infarction [Phase 4]
Phase 4 trial update for alirocumab in patients after acute myocardial infarction, with completed status and posted results.
-
CLINICAL_TRIALS trial_result · 2019-09-06Clinical Trial Update: A Trial of Low-dose Adjunctive alTeplase During prIMary PCI [Phase 2]
Phase 2 trial update evaluating low-dose adjunctive alTeplase during primary PCI in myocardial infarction has completed.
-
FDA approval · 2019-09-03FDA Approved: VALSARTAN — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for valsartan, a generic angiotensin II receptor blocker, for approved labeling…
-
CLINICAL_TRIALS trial_result · 2019-09-03Clinical Trial Update: A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction [Phase 2]
Phase 2 double-blind trial evaluating BAY 1142524 for efficacy and safety after acute myocardial infarction with left ventricular dysfunctio…
-
CLINICAL_TRIALS trial_result · 2019-08-29Clinical Trial Update: Homebased Training With Telemonitoring Guidance in Low to Moderate Risk Patients Entering Cardiac Rehabilitation [NA]
Completed clinical trial evaluating home-based training with telemonitoring guidance for low to moderate risk patients entering cardiac reha…
-
CLINICAL_TRIALS trial_result · 2019-08-26Clinical Trial Update: Risk Stratification in Patients With Preserved Ejection Fraction
Clinical trial update on risk stratification in patients with preserved ejection fraction; study completed with results posted in 2019.
-
FDA approval · 2019-08-20FDA Approved: VALSARTAN — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
The FDA approved a supplemental application for VALSARTAN submitted by Unichem Pharmaceuticals (USA), Inc.
-
CLINICAL_TRIALS trial_result · 2019-08-08Clinical Trial Update: Impact of Morphine Treatment on Platelet Inhibition in Acute Myocardial Infarction [Phase 4]
Phase 4 clinical trial update evaluating how morphine treatment affects platelet inhibition in acute myocardial infarction.
-
FDA approval · 2019-08-07FDA Approved: CLOPIDOGREL BISULFATE — Supplemental Application (Dr.Reddy's Laboratories Inc)
The FDA approved a supplemental application for clopidogrel bisulfate from Dr. Reddy's Laboratories Inc, indicating a supplemental approval …
-
FDA approval · 2019-08-07FDA Approved: ENALAPRIL MALEATE — Supplemental Application (Taro Pharmaceuticals U.S.A., Inc.)
FDA approves a supplemental application for enalapril maleate by Taro Pharmaceuticals U.S.A., Inc., pertaining to an approved product (gener…
-
FDA approval · 2019-08-02FDA Approved: CLOPIDOGREL BISULFATE — Supplemental Application (Dr.Reddy's Laboratories Limited)
FDA approved Dr. Reddy's Laboratories' supplemental application for clopidogrel bisulfate, approving changes to the product's labeling.
-
FDA approval · 2019-08-02FDA Approved: CLOPIDOGREL BISULFATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for clopidogrel bisulfate by Sun Pharmaceutical Industries, Inc. The approval covers the generic…
-
CLINICAL_TRIALS trial_result · 2019-08-01Clinical Trial Update: STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction [Phase 3]
A Phase 3 clinical trial update for STREAM-Strategic Reperfusion using Tenecteplase with antithrombotic treatment in early myocardial infarc…
-
CLINICAL_TRIALS trial_result · 2019-07-31Clinical Trial Update: China Tongxinluo Study for Myocardial Protection in Patients With Acute Myocardial Infarction [Phase 4]
Phase 4 clinical trial update for Tongxinluo in acute myocardial infarction, information on status is currently unknown.
-
CLINICAL_TRIALS withdrawal · 2019-06-13Clinical Trial Update: Early Alirocumab to Reduce LDL-C in Myocardial Infarction [Phase 4]
Phase 4 trial investigating alirocumab to reduce LDL-C in patients with myocardial infarction was withdrawn.
-
FDA approval · 2019-06-12FDA Approved: DIOVAN — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for DIOVAN (valsartan) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2019-06-07Clinical Trial Update: Glutamate for Metabolic Intervention in Coronary Surgery [Phase 3]
Phase 3 trial evaluating glutamate for metabolic intervention in patients undergoing coronary surgery has completed and results have been po…